Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	3066
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	2586
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	2334
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1740
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	578
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	417
Late-Breaking Abstracts	379
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	335
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	283
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	267
Reply	240
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	215
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	206
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	206
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	194
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	168
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	167
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	165
Low-dose chemotherapy remodels hepatic immune landscape and potentiates antitumor response to immune checkpoint blockade in cholangiocarcinoma	164
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	162
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	149
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	143
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	142
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	133
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	133

ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	131
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?	130
Regulatory role and translational potential of CCL11 in liver fibrosis	128
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	126
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	121
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	121
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	116
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium	114
Definition, diagnosis, and treatment of primary biliary cholangitis–autoimmune hepatitis (PBC–AIH) variant: An international expert Delphi consensus	113
Efficacy and safety of infliximab in patients with autoimmune hepatitis	109
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	107
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	105
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	104
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	103
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	100
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	99
	96
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	94
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	94
Genes that fit just right: Unzipping the genome of fatty liver disease	94
In vivo imaging of calcium dynamics in zebrafish hepatocytes	93
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	93
Reply: The CRAPT-M score: Robust enough for clinical practice?	92
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	91
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	91
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	87
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	87
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	86
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	84
Letter to the Editor: Overlooking the important factor: Hypoxia	84
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	83
The international quest for the imaging diagnosis of liver cancer	82
Much more needed in natural history of Alagille syndrome	81
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	78
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells	76
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis	76
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	76
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	75
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	75
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	75
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	75
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	74
Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence	72
Reply: Diabetes and fibrosis—Parallel risks or overlap?	70
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	68
On-treatment LSM: A crystal ball for chronic hepatitis B outcomes	68
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	67
Therapeutic manipulation of the microbiome in liver disease	66
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	65

Immunobiology of primary sclerosing cholangitis	65
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	65
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	65
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	63
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	63
NAFLD‐related hepatocellular carcinoma: The growing challenge	62
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	61
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	61
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	60
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	60
Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency	59
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	59
Retraction: Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma	59
Metabolic dysfunction-associated steatotic liver disease and the heart	59
The clot and the complicated consult	58
Reply: Deep learning and digital pathology power prediction of HCC development in steatotic liver disease	58
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	58
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	57
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	57
Future directions in acute liver failure	56
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	55
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	55
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	55
A bright future: Sustainable treatment of gastric varices	55
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	55
Reply	54
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	54
Reply	54
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	54
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	53
Reply	53
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	53
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	53
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	52
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	52
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	52
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	51
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	51
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	51
Pathway to global elimination of hepatitis B: HBV cure is just the first step	50
Letter to the Editor: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics	50
Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis	49
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages	48
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	48
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	48
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	48
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	48
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	47
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	47
Integrative Hepatology: Enhancing overall health to manage liver disease	47
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	46
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	46
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	46
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	46
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	45
Seeing the scar in higher resolution: AI-derived collagen phenotypes redefine fibrosis in MASLD	45
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	45
AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation	44
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	43
Manuscript best practices: Takeaways from a community conversation	43
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	43
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	43
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	43
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	42
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	42
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	42
Masthead	42
Predicting liver outcomes with biomarker monitoring in MASLD	42
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	42
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	41
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	41
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	41
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	41
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	41
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	41
Letter to the editor: HuR in liver homeostasis	41
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	41
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	40
Stroma-driven intertumoral and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation	40

Intrahepatic cholangiocarcinoma PANoptosidy	40
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	40
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	40
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	40
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	39
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	39
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	39
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	38
Anatomic subsets of cholangiocarcinoma: More different than alike	38
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	38
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	38
Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	38
Lipid nanoparticle-delivered ornithine transcarbamylase mRNA alleviates liver fibrosis in preclinical models	38
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	38
A global action agenda for turning the tide on fatty liver disease	37
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial	37
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	37
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	37
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	37
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	36
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	36
Prognostic significance of mild ascites in patients with cirrhosis	36
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	36
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	36
Telehealth interventions in patients with chronic liver diseases: A systematic review	36
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	36
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	35
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	35
The Liver Meeting: 2025 Abstracts	35
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	35
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	35
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	35
Erratum: Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	34
The evolving role of liver sinusoidal endothelial cells in liver health and disease	34
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	34
Erratum: Single-cell immune profiling of mouse liver aging reveals Cxcl2+ macrophages recruit neutrophils to aggravate liver injury	34
Category Index	34
Category Index	34
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	34
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	34
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	34
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	34
The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome	33
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	33
Retraction: Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective	33
Letter to the Editor: Assessing HCC risk in HBV indeterminate phase	33
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	33
Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding	33
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	33
Abdominal surgery in patients with chronic noncirrhotic extrahepatic portal vein obstruction: A multicenter retrospective study	32
Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing liver transplantation survival benefit	32
MASLD: To screen or not to screen—That is the question	32
Letter to the Editor: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	32
Population-level screening for liver disease: Opportunities and challenges	32
Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event	32
Letter to the Editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	32
Erratum: Late breaking abstracts	32
Reply: More on nonalcoholic/nonmetabolic dysfunction–associated steatohepatitis	32
Deep learning’s crystal ball: Predicting HCC surgery success with multimodal imaging	32
Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	32
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone	31
Hepatitis D virus—still the devil!	31
Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET–activated and β-catenin–mutated hepatocellular carcinoma	31
Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor‐based combination therapies for hepatocellular carcinoma	31
Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis	31
Will noninvasive screening for fibrosis/steatosis open Pandora’s box? Sharing the healthcare burden of state-of-the-art hepatology practice	30
Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk—A multinational cohort study of HBeAg-positive patients	30
Fellows’ Corner	30
Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?	30
Erratum: IL-6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	30
Erratum: KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration	30
Fellows’ Corner	30
Letter to the Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial	30
It's not all about the virus—On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B	30
Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States	30
Video introduction: Special issue on alcohol use disorder and liver disease	30
Erratum: Abstracts	30
Letter to the Editor: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	30
HDV RNA and liver disease progression: What do we know?	30
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma	29
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma	29
Benefit and harm of waiting time in liver transplantation for HCC	29
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi	29
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC	29
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice	29
Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders	29
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma	29
LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism	28
Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B	28
Circulating HBV RNA: From biology to clinical applications	28
Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes HSC activation via SPP1/integrin αvβ1 signaling during liver fibrogenesis	28
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries	28
Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in HCC	28